AbbVie reported that patients continuing Rinvoq in two Phase 3 studies of non-segmental vitiligo showed increasing rates of facial and total-body repigmentation through 76 weeks. The company also released results from a small phototherapy substudy combining the drug with narrowband ultraviolet B treatment.
The ongoing Viti-Up-1 and Viti-Up-2 trials evaluated upadacitinib, marketed as Rinvoq, at 15 mg once daily in adults and adolescents age 12 and older who were candidates for systemic treatment. Patients completed a 48-week placebo-controlled period before entering an open-label extension or a phototherapy substudy.
In Viti-Up-1, 55.1% of patients continuing Rinvoq achieved at least a 75% reduction in facial Vitiligo Area Scoring Index, or F-VASI 75, at week 76, compared with 33.1% at week 48. The proportion achieving at least a 50% reduction in total-body VASI, or T-VASI 50, increased to 42.5% from 29.2%.
In Viti-Up-2, F-VASI 75 responses increased to 47.4% at week 76 from 27.6% at week 48. T-VASI 50 responses rose to 40.1% from 26.2%.
The phototherapy substudy enrolled 84 adults who had not achieved T-VASI 90 at week 48. They were rerandomized to Rinvoq alone or Rinvoq plus twice-weekly whole-body narrowband UVB phototherapy for 28 weeks.
Among patients initially treated with Rinvoq, F-VASI 75 responses were 59.3% with combination treatment and 37.0% with Rinvoq alone. T-VASI 50 responses were 63.0% and 33.3%, respectively.
Safety findings through week 76, and through week 28 in the substudy, were consistent with upadacitinib’s known profile, with no new safety signals reported.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!